



Tardive Dyskinesia: A Complicated Iatrogenic Movement Condition-An Updated Overview of Diagnosis, Management, And Pharmacological Treatment.

¹Sheddi Raffaa Hamad Alshammari,²Yousef Tala Taye Almutairi,³ Sultan Jahaz F. Alotaibi,⁴ Abdullah Mubarak M. Aldosari,⁵ Fahad Shayikh S. Alharthi,
⁶Abdulrhman Nasser S. Abudalli,⁷Abdullah Marzouq Alfraidi,⁸ Fatimah Abdulrahman Nammazi,⁹Salem Mazhor Khalaf Aldosary,¹⁰ Saad Dhaifallah Alamri,¹¹Mishal Fahad Aldossary,¹²Sultan Saad Alshehri

^{1,2,3,4,5,6,7,8,9,10,11,12} KSA, Ministry of Health

Abstract:

Background: Tardive dyskinesia (TD) is a complex iatrogenic movement disorder resulting from prolonged dopamine receptor antagonism. It presents as involuntary abnormal movements such as akathisia, dystonia, and buccolingual stereotypy, predominantly affecting individuals on long-term antipsychotics. Despite the cessation of the causative medication, symptoms often persist, complicating management.

Aim: This review provides an updated overview of the diagnosis, management, and pharmacological treatment options for TD, emphasizing its multifaceted nature and the challenges it presents.

Methods: The article synthesizes current evidence on TD's etiology, pathophysiology, clinical presentation, and treatment strategies. Key diagnostic tools, including the Abnormal Involuntary Movement Scale (AIMS), and therapeutic approaches such as vesicular monoamine transporter (VMAT2) inhibitors, are discussed.

Results: The etiology of TD is linked to first- and second-generation antipsychotics, with the former posing a greater risk. Pathophysiological insights highlight dopamine receptor hypersensitivity, oxidative stress, and neurotransmitter interactions as pivotal contributors. Diagnosis is reliant on symptom persistence post-medication exposure. While treatment options remain limited, valbenazine and deutetrabenazine show efficacy. Preventative measures, including cautious prescribing and regular monitoring, are crucial.

Conclusion: TD remains a challenging condition with significant implications for affected individuals. Comprehensive evaluation and targeted therapies are essential for effective management. Advances in VMAT2 inhibitors offer promise, but prevention through judicious medication use is paramount.

Keywords: Tardive dyskinesia, dopamine antagonism, antipsychotics, movement disorder, VMAT2 inhibitors, diagnosis, management.

Received: 07 October 2023 **Revised:** 22 November 2023 **Accepted:** 06 December 2023

Introduction:

Tardive dyskinesia (TD) is recognized as a complex syndrome comprising various iatrogenic movement disorders arising from dopamine receptor antagonism. These movement disorders encompass akathisia, dystonia, buccolingual stereotypy, chorea, tics, and other involuntary abnormal movements. Although TD is primarily associated with the prolonged use of antipsychotic medications, a range of other pharmacological agents can also precipitate the condition. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), categorizes TD as a medication-induced movement disorder characterized by persistence despite the cessation or modification of the causative medication. According to the DSM-V, a definitive diagnosis of TD requires that symptoms persist for at least one month following the discontinuation of the implicated drug [1][2][3]. Tardive dyskinesia predominantly affects individuals diagnosed with

schizophrenia or bipolar disorder who are treated with antipsychotic agents. Nevertheless, it can manifest in patients with other medical conditions. Moreover, drugs inducing TD may also trigger parkinsonian symptoms. Although the precise mechanisms underlying TD remain elusive, existing data suggest that aberrations in dopamine transporter activity significantly contribute to its pathophysiology.

Etiology:

The etiology of tardive dyskinesia (TD) is predominantly associated with long-term exposure to specific pharmacological agents, including first- and second-generation neuroleptics, certain antidepressants, lithium, and some antiemetic medications. First-generation antipsychotics, which exhibit a stronger binding affinity to dopamine D2 receptors, are particularly linked to a heightened risk of developing TD. These agents significantly disrupt dopaminergic signaling in the dorsal striatum, a key region implicated in motor control. In contrast, second-generation antipsychotics are associated with a reduced risk of TD due to their comparatively weaker dopamine D2 receptor affinity and their concurrent antagonism of serotonin 5-HT2A/2C receptors. This dual mechanism contributes to a diminished diathesis for extrapyramidal side effects, including TD [4][5]. Apart from neuroleptics, other medications have also been implicated in the development of TD. Metoclopramide, a prokinetic agent frequently prescribed to older adults, has been identified as a significant contributor to TD in this demographic. Furthermore, certain antihistamines, as well as antidepressants like amoxapine and fluoxetine, may exacerbate the risk of TD under prolonged use. These drugs, though not primarily dopamine antagonists, may interact with dopaminergic pathways or induce oxidative stress, thereby increasing susceptibility to the disorder. The spectrum of drugs associated with TD underscores the necessity for clinicians to exercise caution when prescribing these medications, especially for long-term use, and to monitor for early signs of movement disorders, particularly in vulnerable populations such as the elderly and individuals with pre-existing neuropsychiatric conditions.

Epidemiology:

The prevalence of tardive dyskinesia is estimated to affect at least 20% of patients treated with first-generation neuroleptics. However, data concerning other causative medications remain less robust, with reported prevalence rates ranging from 1% to 10%. Women, particularly those in middle to older age groups, exhibit a higher susceptibility to TD compared to men. Postmenopausal women are especially vulnerable, with incidence rates reaching 30% following approximately one year of antipsychotic exposure, potentially due to the antioxidant effects of estrogen. Elderly individuals are also at increased risk, likely due to age-related neural and systemic changes. Furthermore, African Americans demonstrate a higher predisposition to TD following prolonged exposure to dopamine antagonists compared to individuals of White ethnicity [6]. Additional risk factors include extended duration of neuroleptic exposure, the presence of extrapyramidal symptoms (EPS), and the use of first-generation antipsychotics over second-generation alternatives. The chronic administration of anticholinergic medications may also amplify the risk of developing TD.




Figure 1: Negative Impacts of TD.

Pathophysiology:

The pathophysiological mechanisms of tardive dyskinesia are complex and multifactorial. First-generation antipsychotics exhibit a higher propensity to induce TD due to their stronger binding affinity to dopamine D2 receptors compared to second-generation agents. Evidence suggests that the occurrence of extrapyramidal symptoms during neuroleptic treatment may serve as a predictive marker for the subsequent development of TD. Beyond dopamine, other neurotransmitter systems, including 5-hydroxytryptophan (5-HT) receptors in the striatum, are implicated in the disorder. These receptors interact with dopaminergic pathways and are critical in modulating motor function. Chronic dopamine receptor blockade is thought to lead to receptor upregulation and heightened postsynaptic sensitivity to dopamine, thereby contributing to TD. Oxidative stress also plays a pivotal role in TD pathogenesis. Dopamine receptor antagonism by antidepressants can enhance dopamine metabolism, resulting in the production of free radicals. This oxidative stress affects the basal ganglia, particularly the striatum and substantia nigra, leading to the manifestation of TD symptoms. Additionally, antipsychotic medications and their metabolites may exert direct neurotoxic effects via oxidative mechanisms. In some cases, discontinuing the causative agent exacerbates TD symptoms, a phenomenon referred to as withdrawal dyskinesia. This effect is hypothesized to result from dopamine receptor upregulation and postsynaptic receptor hypersensitivity. However, this does not fully account for the persistence of TD symptoms long after the offending drug has been discontinued [3].

History and Physical:

Physicians are advised to thoroughly evaluate patients for any existing movement disorders prior to initiating treatment with dopamine D2 receptor antagonists. Clinically, tardive dyskinesia manifests as stereotypic involuntary movements involving the tongue, neck, facial musculature, trunk, and limbs. Buccolingual movements, characterized by phenomena such as lip-smacking, tongue protrusion, perioral activity, chewing motions, or puffing of the cheeks, are prominent. These movements can sometimes be mistaken for stereotypic posturing seen in chronic psychotic conditions; however, tardive dyskinesia is distinctly associated with prolonged dopamine D2 receptor blockade. The onset of tardive dyskinesia is gradual, often initially presenting with subtle aberrant movements that may go unnoticed. Symptoms may emerge as early as one to six months after the initiation of a dopamine receptor antagonist. Diagnosing acute or chronic dyskinesias necessitates a comprehensive patient history, particularly focusing on prior movement disorders and medication exposure, to ensure diagnostic accuracy. Specific movement disorders associated with anti-dopaminergic agents include tardive akathisia, tardive orofacial dyskinesia, tardive dystonia, tardive blepharospasm, and tardive tics. Each of these conditions highlights the diverse spectrum of tardive dyskinesia presentations and underscores the importance of individualized assessment to discern the underlying etiology and manifestation. This comprehensive approach ensures that other potential movement disorders are not misdiagnosed as tardive dyskinesia, thus enabling accurate treatment and management strategies.

Evaluation:

The evaluation of tardive dyskinesia primarily employs standardized rating scales to assess its presence and severity. The Abnormal Involuntary Movement Scale (AIMS) is widely recognized as the principal tool for this purpose. It is recommended that AIMS assessments be conducted at baseline before initiating antipsychotic therapy and at intervals no longer than three months thereafter. During evaluation, the hallmark of tardive dyskinesia is the persistence of symptoms at rest, with partial attenuation during volitional movements—for instance, tongue dyskinesias may subside when the patient is asked to protrude the tongue deliberately. When tardive dyskinesia coexists with cognitive impairment, differential diagnoses should include Huntington's disease, Wilson's disease, or central nervous system tumors. The diagnosis of antipsychotic-induced tardive dyskinesia is contingent upon the persistence of symptoms for at least one month following exposure to neuroleptics for a minimum duration of three months. It is critical to distinguish tardive dyskinesia from withdrawal dyskinesias, which typically resolve shortly after discontinuing the offending antipsychotic. Diagnostic workups may include laboratory tests and imaging

studies. Brain computed tomography (CT) and magnetic resonance imaging (MRI) are typically unremarkable in cases of tardive dyskinesia. However, these modalities are invaluable in ruling out alternative diagnoses such as Huntington's disease, characterized by caudate nucleus atrophy, or Fahr syndrome, marked by basal ganglia calcification. By integrating clinical observation with targeted diagnostic tools, physicians can ensure a precise diagnosis, which is fundamental for developing effective management strategies [1][5][7].

Treatment and Management:

The avoidance of dopamine receptor antagonists is paramount whenever feasible, with a preference for alternative medications associated with a reduced risk of tardive dyskinesia. Chronic use of first-generation antipsychotics should be minimized. To date, therapeutic options for tardive dyskinesia remain limited. The American Academy of Neurology endorses only a few interventions, including clonazepam and ginkgo biloba. Additionally, valbenazine, a vesicular monoamine transporter type 2 (VMAT2) inhibitor, received FDA approval on April 11, 2017, for the treatment of tardive dyskinesia. Evidence from the KINECT 3 trial demonstrated significant improvements in tardive dyskinesia symptoms with valbenazine compared to placebo. Further pharmacological approaches include the use of deutetrabenazine, another VMAT2 inhibitor, which has shown efficacy in clinical trials. Non-pharmacological strategies, such as physical therapy and behavioral interventions, may also offer symptomatic relief. Despite these advancements, primary prevention remains the optimal strategy to mitigate the development of this condition. Physicians should prioritize the use of second-generation antipsychotics with a lower propensity for dopamine receptor antagonism and regularly monitor patients for early signs of movement disorders. This proactive approach, combined with patient education on medication risks, is essential for minimizing the incidence and impact of tardive dyskinesia [8][9][10].

Differential Diagnosis:

The differential diagnosis of tardive dyskinesia encompasses several conditions that may mimic its clinical presentation. These include chorea, complex seizures, essential tremor, Tourette syndrome, tic disorders, Wilson's disease, and Sydenham chorea. A meticulous clinical assessment is crucial to differentiate tardive dyskinesia from these disorders, as management and prognosis vary significantly. Chorea, characterized by brief, irregular, and non-repetitive movements, can be distinguished from the repetitive and stereotypic nature of tardive dyskinesia. Complex seizures may present with involuntary movements, but their episodic nature and association with altered consciousness are key differentiators. Essential tremor, typically bilateral and action-induced, contrasts with the rest-predominant dyskinesias of tardive dyskinesia. Tourette syndrome and tic disorders involve abrupt, repetitive movements or vocalizations that may be voluntarily suppressed to some extent, differing from the involuntary and persistent nature of tardive dyskinesia. Wilson's disease and Sydenham chorea are other important considerations. Wilson's disease, a disorder of copper metabolism, presents with neurological and hepatic symptoms and can be confirmed through laboratory testing and slit-lamp examination for Kayser-Fleischer rings. Sydenham chorea, associated with rheumatic fever, is typically self-limiting and occurs in younger patients. By conducting a thorough clinical evaluation and utilizing targeted diagnostic tests, healthcare providers can accurately differentiate tardive dyskinesia from these conditions, ensuring appropriate treatment and management.

Prognosis:

Tardive dyskinesia is recognized as a chronic, often irreversible condition. While no definitive cure exists, supportive interventions may alleviate symptom severity. Early recognition and intervention are critical to preventing the progression of the disorder. The natural course of tardive dyskinesia varies, with some patients experiencing stabilization of symptoms over time, while others may have a progressive worsening of motor disturbances. Factors influencing prognosis include the duration and type of dopamine receptor antagonist exposure, as well as individual patient characteristics such as age and comorbidities. Younger patients and those with shorter exposure durations may have a more favorable outlook compared to older individuals with prolonged exposure to neuroleptics. Supportive measures, such as pharmacological interventions with VMAT2 inhibitors and non-pharmacological therapies like physical rehabilitation, can

enhance quality of life. Additionally, minimizing or discontinuing exposure to offending agents may prevent further symptom progression. However, in many cases, the motor disturbances persist despite these interventions. Ongoing research into novel therapeutic approaches, including neuroprotective agents and advanced neuromodulation techniques, offers hope for improved outcomes. Until such treatments become widely available, the focus remains on prevention, early detection, and symptom management to mitigate the impact of tardive dyskinesia on patients' lives. By adopting a multidisciplinary approach to care, clinicians can address the complex needs of affected individuals, promoting better functional and psychological well-being.

Complications:

Tardive dyskinesia primarily manifests as a progressive motor disturbance characterized by involuntary movements that can significantly disrupt the patient's quality of life. Beyond the physical discomfort, individuals with this condition often experience profound social embarrassment due to the visibility of their symptoms. While the condition is not inherently fatal in most cases, severe involvement of the laryngeal and diaphragmatic muscles can lead to life-threatening complications. Such cases necessitate immediate medical intervention to prevent fatal outcomes, as these involuntary contractions can impair vital respiratory functions. The psychosocial burden of tardive dyskinesia also underscores the importance of early detection and intervention to minimize the long-term impacts on both physical and emotional well-being. It is essential for healthcare providers to recognize the multifaceted implications of this disorder, not only focusing on physical symptoms but also addressing the psychological and social dimensions associated with it.

Consultations:

The effective management of tardive dyskinesia often requires a multidisciplinary approach involving several specialists. An ophthalmologist plays a vital role in assessing the potential for Wilson's disease, which may present with similar clinical features. Neurologists and movement disorder specialists provide advanced diagnostic and therapeutic insights, ensuring that the manifestations of tardive dyskinesia are accurately distinguished from other movement disorders and effectively managed. Psychiatric consultation remains integral to optimizing the ongoing management of neuroleptic therapy, particularly for patients requiring antipsychotic treatment despite the emergence of tardive dyskinesia. Psychiatrists are instrumental in determining appropriate adjustments in psychotropic regimens to mitigate symptom progression while addressing the underlying psychiatric conditions. Collaborative interprofessional discussions among these specialists are imperative to ensure holistic patient care. This approach facilitates the precise identification of the disorder, the minimization of symptom exacerbation, and the development of individualized management strategies tailored to the patient's unique clinical circumstances.

Deterrence and Patient Education:

Preventing tardive dyskinesia is the most effective strategy for mitigating its impact. Primary prevention involves prescribing the lowest effective dose of antipsychotic medications for the shortest feasible duration. Patients receiving these medications should be closely monitored for early signs of tardive dyskinesia. If symptoms emerge, it is recommended to reduce the dosage or discontinue the offending agent. In patients who require ongoing antipsychotic therapy, clozapine is often the preferred alternative, as its association with tardive dyskinesia is significantly lower compared to other antipsychotics. Educating patients and caregivers about the risks of tardive dyskinesia and the importance of adherence to prescribed treatment regimens is critical. Additionally, healthcare professionals should provide information on the early identification of symptoms and the importance of timely communication with clinicians. Structured educational programs targeting both patients and caregivers can empower them to recognize early signs of the disorder, thus enabling prompt intervention to prevent irreversible complications.

Enhancing Healthcare Team Outcomes:

The diagnosis and management of tardive dyskinesia necessitate a cohesive interprofessional team approach. Primary care clinicians often detect the initial signs of the disorder during routine follow-ups,

prompting collaboration with specialists, including pharmacists, nurses, and movement disorder experts. Pharmacists play a critical role in reviewing medication profiles, identifying potential risk factors, and advising on alternatives to dopamine-blocking agents. They also educate patients about the importance of wearing medical alert bracelets to warn against the administration of contraindicated drugs. Nurses, on the other hand, are pivotal in monitoring patients for symptom progression or improvement and promptly communicating observations to the healthcare team. This ensures timely adjustments to therapeutic interventions. Clinicians must exercise caution when prescribing dopamine-blocking agents, particularly for high-risk populations such as individuals with schizophrenia or developmental disabilities. A robust interprofessional framework enhances patient outcomes by promoting early diagnosis, optimizing medication management, and ensuring continuous monitoring and patient education. With such collaboration, the risk of severe tardive dyskinesia can be significantly reduced [11] [12].

Outcomes:

The outcomes associated with tardive dyskinesia are variable and often influenced by factors such as patient age, medication history, and the duration of antipsychotic therapy. Some studies report symptom improvement following dose reduction or discontinuation of the offending antipsychotic agent, while others indicate persistent symptoms despite these adjustments. Long-term observations suggest that tardive dyskinesia remains in approximately 10–30% of affected individuals, with younger patients experiencing better outcomes when treated with lower doses for shorter periods. Transitioning to low-potency antipsychotics has also been shown to reduce the risk of tardive dyskinesia. Recently, the FDA-approved valbenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, has shown promise in alleviating symptoms. Clinical trials have demonstrated their efficacy and safety, though concerns about potential conflicts of interest among researchers necessitate further independent studies to validate these findings. Overall, early intervention, careful medication management, and ongoing research are essential to improving long-term outcomes for patients with tardive dyskinesia [13-14].

Conclusion:

Tardive dyskinesia (TD) represents a persistent and debilitating challenge in clinical practice, particularly among individuals receiving long-term antipsychotic therapy. The complexity of its pathophysiology, involving dopamine receptor hypersensitivity, oxidative stress, and other neurotransmitter disruptions, underscores the multifactorial nature of this condition. Prolonged use of first-generation antipsychotics significantly elevates the risk, with vulnerable populations, including postmenopausal women and the elderly, disproportionately affected. Accurate diagnosis hinges on the use of validated tools such as the Abnormal Involuntary Movement Scale (AIMS) and careful differentiation from other movement disorders. This precision is critical for tailoring management strategies to individual needs. Current treatment options, such as valbenazine and deutetrabenazine, demonstrate clinical efficacy and offer symptomatic relief, though they fall short of providing a definitive cure. Non-pharmacological interventions, including physical therapy, complement pharmacological approaches and highlight the need for a multidisciplinary care model. The importance of prevention cannot be overstated. Clinicians must prioritize second-generation antipsychotics, which exhibit a lower risk of TD, and ensure regular monitoring for early signs of movement disorders. Educating patients on the potential side effects of long-term antipsychotic use is equally crucial for informed decision-making. Despite advancements in understanding and managing TD, significant gaps remain, particularly in identifying predictive biomarkers and developing curative therapies. Future research should focus on elucidating the molecular mechanisms underpinning TD and exploring innovative treatment modalities. By integrating evidence-based practices with preventative strategies, healthcare providers can mitigate the impact of TD and improve outcomes for affected individuals. Ultimately, addressing TD requires a proactive and patient-centered approach, balancing the therapeutic benefits of antipsychotics with the risks they pose to motor function and quality of life.

References:

1. D'Abreu A, Friedman JH. Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review. Tremor Other Hyperkinet Mov (N Y). 2018;8:570.
2. Kim DD, Barr AM, Chung Y, Yuen JWY, Etminan M, Carleton BC, White RF, Honer WG, Procyshyn RM. Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review. CNS Drugs. 2018 Oct;32(10):917-938.
3. Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. Neurol Ther. 2018 Dec;7(2):233-248.
4. Erbe S. [Prevention and Treatment of Antipsychotic-induced Tardive Dyskinesia]. Fortschr Neurol Psychiatr. 2019 Apr;87(4):217-224.
5. Walther S, Stegmayer K. [Diagnosis and treatment of motor phenomena in schizophrenia spectrum disorders]. Ther Umsch. 2018 Jun;75(1):31-36.
6. Correll CU. Epidemiology and Prevention of Tardive Dyskinesia. J Clin Psychiatry. 2017 Nov/Dec;78(9):e1426.
7. Jain R, Correll CU. Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis. J Clin Psychiatry. 2018 Mar/Apr;79(2)
8. Kane JM, Correll CU, Nierenberg AA, Caroff SN, Sajatovic M., Tardive Dyskinesia Assessment Working Group. Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop. J Clin Psychiatry. 2018 May/June;79(3)
9. Kim AP, Baker DE, Levien TL. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia. Consult Pharm. 2018 Apr 01;33(4):201-209.
10. Caroff SN, Aggarwal S, Yonan C. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. J Comp Eff Res. 2018 Feb;7(2):135-148.
11. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):1-30.
12. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988 Nov;39(11):1172-7.
13. Essali A, Soares-Weiser K, Bergman H, Adams CE. Calcium channel blockers for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Mar 26;3(3):CD000206.
14. Vasan, S., & Padhy, R. K. (2023). Tardive dyskinesia. In *StatPearls [Internet]*. StatPearls Publishing.

خلل الحركة المتأخر: حالة معقدة من اضطرابات الحركة الناتجة عن العلاج الطبي - نظرة محدثة على التشخيص، الإدارة، والعلاج الدوائي المخصص:

الخلفية: خلل الحركة المتأخر (TD) هو اضطراب حركي معقد ناتج عن استخدام طويل الأمد لمضادات مستقبلات الدوبامين. يظهر في صورة حركات غير إرادية مثل الأكاتيزيا، والديستونيا، والنمطيات القموية اللسانية، ويؤثر بشكل أساسي على الأفراد الذين يتناولون مضادات الذهان لفترات طويلة. غالبًا ما تستمر الأعراض حتى بعد التوقف عن الدواء المسبب، مما يجعل الإدارة صعبة.

الهدف: تقدم هذه المراجعة نظرة محدثة حول تشخيص خلل الحركة المتأخر وإدارته وخيارات العلاج الدوائي، مع التركيز على طبيعته المتعددة الأوجه والتحديات التي يفرضها.

الطرق: يدمج المقال الأدلة الحالية حول أسباب TD، وآلياته الفيزيولوجية المرضية، وصوره السريرية، واستراتيجيات علاجه. تشمل المناقشة أدوات التشخيص الرئيسية مثل مقياس الحركات غير الإرادية غير الطبيعية (AIMS)، والنهج العلاجي مثل مثبطات ناقل أحادي الأمين الحويصلي (VMAT2). النتائج: ترتبط أسباب TD بمضادات الذهان من الجيل الأول والثاني، حيث يشكل الجيل الأول خطرًا أكبر. تسلط الرؤى الفيزيولوجية المرضية الضوء على فرط حساسية مستقبلات الدوبامين، والإجهاد التأكسدي، وتداخلات الناقلات العصبية كعوامل رئيسية. يعتمد التشخيص على استمرار الأعراض بعد التعرض للدواء. على الرغم من محدودية خيارات العلاج، أثبت كل من الفالينازين والديوترايبينازين فعالتهما. تعتبر التدابير الوقائية، بما في ذلك وصف الأدوية بحذر والمراقبة المنتظمة، أمورًا أساسية.

الاستنتاج: لا يزال خلل الحركة المتأخر حالة صعبة ذات تأثيرات كبيرة على الأفراد المصابين. التقييم الشامل والعلاجات المستهدفة ضرورية للإدارة الفعالة. تقدم مثبطات VMAT2 تقدمًا واعدًا، لكن الوقاية من خلال الاستخدام الحكيم للأدوية تظل الأهم.

الكلمات المفتاحية: خلل الحركة المتأخر، مضادات الدوبامين، مضادات الذهان، اضطراب الحركة، مثبطات VMAT2، التشخيص، الإدارة.